INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 3 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $313 | -17.6% | 6,000 | 0.0% | 0.02% | -25.0% |
| Q2 2023 | $380 | +9.5% | 6,000 | -6.2% | 0.03% | -3.0% |
| Q1 2023 | $347 | +2.4% | 6,400 | 0.0% | 0.03% | -15.4% |
| Q4 2022 | $339 | -99.9% | 6,400 | 0.0% | 0.04% | +5.4% |
| Q3 2022 | $298,000 | -18.4% | 6,400 | 0.0% | 0.04% | -15.9% |
| Q2 2022 | $365,000 | -9.7% | 6,400 | -3.0% | 0.04% | +2.3% |
| Q1 2022 | $404,000 | +8.6% | 6,600 | -7.0% | 0.04% | +4.9% |
| Q4 2021 | $372,000 | +40.4% | 7,100 | 0.0% | 0.04% | +5.1% |
| Q3 2021 | $265,000 | -27.8% | 7,100 | -21.1% | 0.04% | -29.1% |
| Q2 2021 | $367,000 | +10.2% | 9,000 | -8.2% | 0.06% | +3.8% |
| Q1 2021 | $333,000 | -4.9% | 9,800 | -10.9% | 0.05% | 0.0% |
| Q4 2020 | $350,000 | +26.4% | 11,000 | +1.9% | 0.05% | +26.2% |
| Q3 2020 | $277,000 | +1.8% | 10,800 | +1.9% | 0.04% | +2.4% |
| Q2 2020 | $272,000 | – | 10,600 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |